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Abstract
Indicators that summarise the health status of a population and that
provide comparable measures of a population disease burden are
increasingly vital tools for health policy decision making. Decisions
concerning health systems across the world are greatly affected by
changes in disease profiles and population dynamics, and must devel-
op the capacity to respond to such changes effectively within the
resources of each nation. Decisions must be based on evidence of the
patterns of diseases, their risk factors and the effectiveness of alterna-
tive interventions. This paper focuses on the main approaches used
for developing summary measures that include mortality and morbidi-
ty occurring in a population. It discusses the rationale for composite
measures and reviews the origins of each main approach. The paper
also examines methodological differences among these approaches
making explicit the value choices that each entails, outlines the
advantages and limitations of each measure, and shows how they
relate to one another.
Introduction
Recent developments in the measurement of population health sta-
tus and disease burden include the increasing use of summary com-
posite measures of health that combine the mortality and morbidity
effects of diseases into a single indicator. Measures of health status
that combine mortality and morbidity facilitate comparisons within
and across populations. They are used to estimate the quantitative
health benefits from interventions and serve as tools to assist in the
allocation of resources. The construction of such measures entails two
major processes: the measurement of healthy life, including losses of
time from mortality and disability; and valuing life, which incorporates
issues of duration, age, extent of future life, productivity, dependency,
and equity.1
This paper focuses on the main approaches used for developing
composite measures of population health status that summarise mor-
tality and morbidity occurring in a population through the use of a sin-
gle number. It discusses the rationale for composite measures, reviews
the origins of selected main approaches, examines methodological dif-
ferences among these approaches, makes explicit the value choices
that each entails, outlines the advantages and limitations of each, and
shows how they relate to one another.
Summary measures 
Two types of composite summary measures have been developed:
health gap measures such as healthy life years (HeaLYs), disability-
adjusted life years (DALYs), and quality-adjusted life years (QALYs),
and health expectancies such as disability-free life expectancy (DFLE)
or health-adjusted life expectancy (HALE). Both types use healthy life
time lost through disability and death as a common measure of the
impact of mortality and non-fatal health outcomes. These two types of
measures are complementary and have been discussed by Murray and
Lopez.2,3 HeaLYs, DALYs, and QALYs are developed on the basis of dis-
ability and death attributable to a specific disease in an individual per-
son. In their construction, great care is taken that there is categorical
attribution using the International Classification of Disease (ICD) so
that each event (death or disability) is mutually exclusive and collec-
tively exhaustive. With these measures, therefore, summing deaths
and disabilities from each disease provides the total amount of death
and disability for the population (a property termed additive decompo-
sition). Health gap measures have this property whereas health
expectancies do not.
A number of composite summary indicators for burden of disease
assessment have been developed. We shall review four families. Three
of these are of the health gap type: the healthy life year (HeaLY), the
disability-adjusted life year (DALY), and the quality-adjusted life year
(QALY), and one is of the health expectancy type, namely the health-
adjusted life expectancy (HALE). These metrics are the most common-
ly used and are, therefore, discussed below.
Healthy life year
We discuss the healthy life year first because it is conceptually
straightforward, serves as a prototype for other health gap indicators,
and was the first of the composite measures to be used as a tool in
national health planning.4 In the early 1980s the Ghana Health
Assessment Team undertook a study to assess the burden of disease in
low- and middle-income countries (LMICs). The healthy life year
(HeaLY) approach is a direct derivative of that work in Ghana.5 The
Significance for public health
Health programmes are evaluated for impact on the burden of mortality, mor-
bidity and disability in populations. Increasingly, summary measures of pop-
ulation health, such as healthy life years (HeaLYs), disability-adjusted life
years (DALYs), and quality-adjusted life years (QALYs), are being used to
assess the impact and effectiveness of health interventions, and are useful
tools for guiding resource allocation and planning efficient (and equitable)
health care systems. A thorough understanding of these measures is crucial
for public health professionals.










HeaLY combines the amount of healthy life lost due to death with that
lost due to morbidity. Life lost from a disease due to death is based on
the years of life expectancy had the disease not occurred. The informa-
tion needed to estimate this, in addition to the incidence rate and case
fatality ratio, is the age of disease onset, the age of death, and the
expectation of life at these ages. Life lost from disability must have
comparable dimensions to that lost due to death. The HeaLY includes
three components for disability: case disability ratio (CDR, analogous
to the case fatality ratio), extent of disability, and duration of disabili-
ty. The CDR and duration of disability can be determined objectively,
but assessment of the extent of disability, which ranges from 0 (no dis-
ability) to 1 (equivalent to death) may have a substantial subjective
element.1
The healthy life approach focuses on the pathogenesis and natural
history of disease as the conceptual framework for assessing morbidi-
ty and mortality, and for interpreting the effects of various interven-
tions. Interventions may also be directed at reducing identifiable risk
factors, such as tobacco smoking or risky sexual behaviour. To the
extent that risk reduction can be translated into disease reduction, the
approach to measuring the benefits and costs of a risk reduction inter-
vention programme remains the same as that for disease reduction.
For the purpose of estimating healthy life lost from disease or gained
from interventions, disease is defined according to the 10th revision of
the International Statistical Classification of Diseases and Related
Health Problems (known as the ICD-10), a medical classification list
for the coding of diseases, signs and symptoms, abnormal findings,
complaints, social circumstances, and external causes of injury or dis-
eases.6 The definition of variables and formula to calculate HeaLYs are
summarised in Table 1. 
The expectation of life in HeaLYs, as with DALYs, is based on expec-
tations of what should occur under optimal circumstances. For exam-
ple, the life expectancy for women in Japan based on the West model
life tables (The West model life table gives female life expectancy for
women in Japan as 82.5 years).7,8 The CDR for most diseases is 1
because all cases labelled as a disease in the ICD are, therefore, dis-
abled to varying degrees and duration. The duration of disability can be
either temporary or permanent (lifelong). If the disability is temporary,
then Dt is the duration of that disability until recovery (Table 1). If the
disability is permanent and the disease does not affect life expectation,
then the expectation of life at age of onset of disease can be used.  On
the other hand, if the disability is permanent and the disease does
reduce life expectancy, then the expectation of life at age of onset
reduced by the difference between ages of fatality and onset can be
used. A disability severity scale needs to be used to estimate extent
(severity) of the disability. This review does not attempt to provide a
critique of the methods and scales used in assessing the extent of dis-
ability indicator used in QALYs or DALYs but rather focuses on the basic
constructs that are involved in each of these approaches outlining how
they relate to one another. 
The healthy life lost from death and from disability are added and
expressed as the total years of life lost per 1000 population per year; the
loss is attributed to the year in which disease onset occurs and includes
the stream of life lost from disability and death at any time after onset,
even if these events happen many years later. This is a prospective view
of the event (disease onset) and its natural history (or as modified by
interventions) over time.
An important benefit of the HeaLY formulation is that the effects of
different kinds of interventions can be readily explored to determine
their expected gains in healthy life. Interventions may usefully be
divided into two broad categories: those that are used to prevent the
initiation of the disease process, and those that are used to treat a dis-
ease process already under way, which includes rehabilitative care.
Some interventions fall into both categories. The primary effect of pre-
ventive strategies is to reduce the incidence of new cases of disease.
The main effects of treatment strategies are to interfere with the nat-
ural history of the disease process, thereby reducing the case fatality
and/or case disability ratios or extending life by providing a later age at
death for conditions such as diabetes and AIDS (for an example of the
application of the HeaLY measure see Hyder et al.5
Disability-adjusted life year
The disability-adjusted life year (DALY) is a health gap population
summary measure that combines time lost due to disability with that
which is due to death (life that would have been expected had the dis-
ease not occurred) in a manner similar to the healthy life year meas-
ure. It first appeared in the World Development Report of 19939 and has
become the most widely used composite measure of population
health.2,3,10-13 DALYs are calculated as two separate components for the
measurement of life lost due to disease, and they also directly include
three social value choices. The two components are: i) years of life lost
(YLL), the loss of healthy life from death; and ii) years of life lived with
disability (YLD), the loss of healthy life from disability. The social value
choices that can be included are: i) life expectation values; ii) discount
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Table 1. Variables for estimating healthy life years (HeaLYs).
Description Unit Symbol
Incidence rate per 1000 population per year per 1000 per year I 
Average age at onset years Ao
Average age at death years Af
Expectation of life at age of onset years E(Ao)
Expectation of life at age of death years E(Af)
Case fatality ratio: proportion of those developing the disease who die from the disease 0.00-1.00 CFR
Case disability ratio: proportion of those developing the disease who have disability from the disease 0.00-1.00 CDR
Extent of disability (from none to complete disability equivalent to death) 0.00-1.00 De 
Duration of disability in years years Dt°
Healthy life years lost per 1000 population per year HeaLYs per 1000 per year HeaLYs
HeaLY = I * {[CFR*{E(Ao)-[Af - Ao]}] + [CDR*De*Dt]}
°Disability can be either permanent or temporary. -If temporary, then Dt = duration of that disability, i.e. until recovery or death. -If permanent and disease does not affect life expectation Dt = E(Ao). -If
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rates for future life; and iii) weighting for life lived at different ages, as
discussed below. The calculation for YLL in a population uses the age
distribution of all deaths by cause in one year multiplied by life expec-
tation at each age to estimate loss of life for each disease that would
have been expected if that disease had not occurred. The expectation
of life is obtained from a model life table based on best achievable low
levels of mortality, such as in Japan,8 and thus the DALY (and the
HeaLY) directly incorporates this social value choice. 
For disability, the DALY uses estimates of incidence, duration, and
severity to calculate the time lived with disability (YLD) for each dis-
ease. The YLD component equals the number of incident cases in the
period multiplied by the average duration of disease multiplied by a
weight factor for the degree of severity (extent) of disability from the
disease. The second social value choice directly incorporated in the
DALY is the discount rate of 3% per annum. This social time preference
has been used for most estimates; however, DALY results discounted at
0% are also available. 
The third social value choice concerns weighting life lived at differ-
ent ages. DALYs are age-weighted according to an arbitrary exponential
curve designed to give the most value to life lived as a young adult.5,9
Weighting by age was the most controversial component of the DALY
when they appeared and caused great dissent among other health pro-
fessionals (see below Valuing Life Lived at Different Ages).2 Recent
DALY listings of Global Burden of Disease (GBD) studies also include
results with no age weighting (all years equally valued).14 It has been
argued that age weighting of DALYs does not affect final results, but
this depends on the purpose for making the estimates and has been
challenged.5,15-17 The definition of variables and formula to calculate
DALYs are summarised in Table 2.
Note that an important difference between the HeaLY and DALY is
that the starting point for the HeaLY is the onset of disease; the loss of
healthy life is based on the natural history of the disease (as modified
by interventions). This is true for the YLD component of the DALY, but
the YLL is based on mortality in the current year. In a steady state there
is no difference, but when there is a changing incidence, such as with
HIV in many parts of the globe, the DALY approach can greatly under-
state the true situation.18
The calculation for DALYs can be expressed in the form of an inte-
gral that was first published in the World Bank literature.2 This single
equation incorporating all technical and value choices has the advan-
tage of standardisation to ensure comparability of the multiple calcula-
tions undertaken in the Global Burden of Disease studies and, certain-
ly, it has greatly facilitated the actual computations.  However, for
national and local priority setting, it may be preferable to use an indi-
cator constructed such that the social value choices can be adjusted to
suit national and local preferences.1,5,19 Recent DALY formulations
allow for this; as a result, it is useful to think of DALYs as a family of
related measures.13
HeaLYs and DALYs are both health gap measures and can be consid-
ered in the same family of measures. In fact, DALYs exactly equal
HeaLYs when: i) the condition in question is in a steady state or equi-
librium (that is the Incidence, CFR, and Disability variables remain
constant during the time intervals under consideration); ii) age
weighting is not applied (K=0); and iii) the same measures of disabil-
ity (weights) are used (Table 2).  
Quality-adjusted life year
The quality-adjusted life year (QALY) was introduced in 1976 to pro-
vide a guiding principle for selecting among alternative tertiary health
care interventions.20 The idea was to develop a single measure of qual-
ity of life in order to compare expected outcomes for a disease from dif-
ferent interventions; a measure that valued possible health states for
their quality of life as well as their duration. 
The central notion behind the QALY is that a year of life spent in one
health state may be preferred to a year spent in another. It is a generic
measure that sums time spent in different health states using weights
for each health state on a scale of 0.00 (dead) to 1.00 (perfectly
healthy) i.e. the arithmetic product of duration of life and a measure of
quality of life (health state weight) (Table 2). So, five years of perfect
health = 5 QALYs while two years in a state measured as 0.5 of perfect
health followed by three years of perfect health = 4 QALYs. 
The QALY was originally developed as a differentiating indicator for
individual choices among tertiary health care procedures, not as a
measure of disease burden in a population. It was used to assess indi-
vidual preferences for different health outcomes from alternative inter-
ventions.1 Since its introduction, a wide variety of QALY measures have
been developed, along with an extensive literature on alternative meth-
ods incorporating a range of disability domains and a diversity of meth-
ods to assign weights to generate QALYs.21,22 The most widely used
measure is the EQ-5D (European Quality of Life with Five Domains and
Hyder et al.
Table 2. Variables and formula for Disability Adjusted Life Years (DALYs) and basic formulation for Quality-Adjusted Life Years
(QALYs).
Description Unit Symbol
Years of life lost due to death before expectation of life had the disease not occurred years YLL
Years lost due to disability multiplied by disability weight years YLD
Number of deaths number N
Number of incident cases number I
Life expectation or duration of disability years DW
Discount rate % r
Age-weighting correction constant  0.1658 C 
Parameter for age-weighting function   0.04  b
Age at onset of disease years a 
Parameter for setting age-weighting 1 or 0 K  
DALY = YLL + YLD where YLL = N Ce(ra) / ( +r)2 [e ( + r) (L+a) [-( +r) (L+a)-1] - e ( + r)a [–( r)a-1]]
YLD = I DW { K Ce(ra) / ( +r)2 [e ( +r)(L+a) [-( + r)(L+a)-1] - e ( + r)a [–( r)a-1]] + (1-K) (L/r) (1– e  rL )}
QALYs (basic formulation) QALY = Life years lived (duration) x quality of life (health state) indicator° 










3 levels of quality for each Domain).23
Perhaps the most important use of QALYs has been as a common
denominator to measure utility in cost-utility analysis (CUA) and effec-
tiveness in cost-effectiveness analysis (CEA) to assist in resource allo-
cation among alternative health interventions by ranking interventions
in terms of cost per QALY.21,24 An early and widely publicised attempt to
make the best use of health care resources by maximising QALYs per
dollar spent was the well-intentioned but rather unfortunate effort in
Oregon in the early 1990s.25,26 In the UK, as part of its 1997 NHS
reforms, the National Institute for Clinical Excellence (NICE) was cre-
ated to advise about the effectiveness and cost effectiveness of various
health interventions. In order to introduce economic considerations in
addition to medical judgments for the allocation of resources, NICE has
produced a large collection of studies on the cost per QALY produced by
the interventions it appraises (www.nice.org.uk).
The QALY as originally used is essentially equivalent to the YLD of
the DALY. In fact, it would be similar to the YLD when: i) there is no dis-
counting (r = 0); ii) no age weighting is used (K=0); and iii) the same
disability weights are used. More recently (as used in some cost-effec-
tiveness studies) QALYs have also incorporated life expectation. 
The health-adjusted life expectancies
There are several types of health expectancies in the literature.
During the 1990s, disability free life expectancy (DFLE) and related
measures were calculated for many countries.27,28 However, these
measures incorporate a dichotomous weighting scheme in which time
spent in any health state categorised as disabled is assigned, arbitrar-
ily, a weight of zero (equivalent to death). Thus, DFLE is not sensitive
to differences in the severity distribution of disability in populations. In
contrast, the disability-adjusted life expectancy (DALE) adds up expec-
tation of life for different health states with adjustment for severity
weights. 
The term DALEs was replaced by the term HALEs (health-adjusted
life expectancy) by the World Health Organization (WHO) in 2001 and
this is the term that we will use here. The HALE is a composite summa-
ry measure of population health status that belongs to the family of
health expectancies. It summarises the expected number of years to be
lived in what might be termed the equivalent of full health. Some con-
sider the HALE to provide the best available summary measure for
measuring the overall level of health for populations.27 The WHO has
used it as a measure of the average level of health of the populations of
member states for annual reporting.
Health expectancy indices combine the mortality experience of a
population with the disability experience. Some versions of the HALE
are calculated using the prevalence of disability at each age in order to
divide the years of life expected at each age according to a life table
cohort into years with and without disability. Mortality is captured by
using a life table method, while the disability component is expressed
by additions of prevalence of various disabilities within the life table.
This indicator allows an assessment of the proportion of life spent in
disabled states. When compared with the total expectation of life, this
translates to a measure of the total disability burden in a population.
The various methods and specific indicators have been compared in
the literature.28 Alternative methods are given in the WHO National
Burden of Disease Studies manual.27
As originally designed, the HALE does not relate to specific diseases
but rather to the average extent of disability among that proportion in
each age group that is disabled. The lack of correlation between a con-
dition or disease entity and the measure makes it intuitively less valu-
able for resource allocation and cost-effectiveness calculations.
Valuing life: social issues
To construct composite measures of population health, important
social value choices must be made. Choices about what expectation for
life should be used and about valuing life lived at different ages, valu-
ing future life as compared with the present, valuing life in terms of
economic and social productivity, and valuing equity in relation to effi-
ciency all raise major ethical concerns.Expectation of life 
Years of life lost due to death and to chronic disability are based on
life expected had the disease not occurred. To estimate the expectation
of life in a population, a choice must be made as to whether to use a
local, national or a model life table. This choice should be determined
by the purpose of the study. For assisting in national and local decision
making, it may be more suitable to use national life tables based on the
mortality and fertility of the population in question than on model life
tables. On the other hand, a model life table can be selected to reflect
the best health state possible in the world, such as the Coale and Guo
West model.8 This selection allows a fair comparison with other coun-
tries. For example, from a global perspective, it would be unfair to use
national life tables to compare gains that could be achieved from a par-
ticular intervention in Ghana with those in the United Kingdom, even
if both costs and lives saved were the same in each country. The reason
is that those lives saved in Ghana would have a lower life expectancy
than those in the United Kingdom, resulting in less healthy life saved
for the same expenditure. From the global viewpoint, such use would
erroneously prioritise the action to fund the intervention in the United
Kingdom because it would produce more healthy life per expenditure
than it would in Ghana. 
Model life tables in common use are the United Nations model life
tables and the Coale and Demeney life tables which were used in the
HeaLY and GBD studies.2,5,8 The West model life table does not refer to
any geographical entity but is considered to represent a mortality pat-
tern typical of the most technologically advanced countries. Level 26
has a female life expectancy at birth of 82.5 years, as actually experi-
enced by women in Japan; therefore, it represents a level that could be
achievable elsewhere. Valuing life lived at different ages 
Age weighting refers to the valuing of a year of life according to the
age at which it is lived. This immediately raises questions as to the
basis for valuing human life. Is a day of anyone’s life of the same value
as that of anyone else? Does the value vary with age, economic produc-
tivity, or social status? Should life itself be valued separately from what
is done with that life? 
The Ghana Health Assessment Team judged that all human life was
intrinsically valuable and that a given duration of any life was equal in
value to that of any other life.4 The valuing of a year of life equally, irre-
spective of age, has been considered egalitarian.1,29 This choice
remained in the development of the HeaLY approach: a year of life lived
at any age is equally valued. 
The original DALY formulation assigned a quasi-exponential func-
tion to provide a value chosen so that life lived as a dependent (e.g.,
infants, children, and the elderly) is given less value than life lived dur-
ing the productive years. In this decision, the intrinsic value of life
increases from 0 at birth to a maximum at 25 years of age and declines
thereafter, so that a day of life of a 50-year old is worth about 25% less
than that of a 25-year old. Paradoxically, the age weighting used in the
original DALY formulation leads to higher valuation of life lived at
under 15 years of age than does the HeaLY formulation, in which life
lived at all ages is valued equally.5,16 Current formulations of the DALY
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leave age weighting as an option, and such weighting is not used with
the HALE. If it is decided that healthy life should be valued according to
economic and social productivity, then an alternative to age weighting
might be to explicitly add a productivity factor or subtract for the soci-
etal costs of dependents, such as education (see below Valuing life for
its economic productivity). Discounting
Discounting is the process for determining the present value of
future events. Social time preference takes into account the phenome-
non that people value events at present more highly than those in the
future (independent of inflation and of uncertainty). For investments
in other sectors, time preference is normally taken into account by dis-
counting future returns and costs by some appropriate discount rate. It
can be considered the inverse of an interest rate. The main issue con-
cerning discounting in relation to summary measures is whether dis-
counting life itself is appropriate, though discounting the future value
of what is produced by healthy life appears to be less contentious.1
Discounting has been applied in the health sector because both the
losses from a disease and the benefits from a health intervention often
occur in the future.30 An intervention today may not produce immedi-
ate benefits (such as in immunisation), or it may result in benefits
being sustained over a long time (such as in supplementary nutrition).
The costs for these interventions must be borne now, but benefits take
place in the future and are less valued than if they could occur now.
This is equivalent to investing money now in order to obtain more in
the future. Because of social time preference, a healthy life year now
has greater intrinsic value to an individual or community than one in
the future.31,32
There is no consensus on the choice of a discount rate in health, but
most agree that it should be lower than that in the private commercial
sector. The World Development Report (WDR) in 1993 and the GBD
studies discounted at 3% a year; in lieu of other information, this rate
has come to be used in most international health cost-effectiveness
studies.9 However, the impact of using a range of different discount
rates, including zero, should be explored with each study. Valuing life for its economic productivity
In general, productivity may be attributed to adults aged 15-64 years
of age, and individuals in these age groups could be given a higher
value for their time spent at these ages. Those under 15 years of age
and over 65 may be considered as dependents and given a lower value.
There are many variations for differential valuing, including type of
employment. People at different socio-economic levels in a society are
expected to have different capacities for productivity, yet to value life
according to income levels or social class would not seem fair, and
would not generally be acceptable. In poor countries, the value of mar-
ginal wages for subsistence agriculture is negligible, but the value of
the workers’ lives certainly is not. 
A fundamental question is whether to consider adding a productivi-
ty component to the summary measure. Health issues do not readily
conform to the requirements of market economics; information is inad-
equate, and misinformation is rife on the part of the providers as well
as the public. Externalities from good health are generally large.
Demand for costly services is largely determined by the health care
providers rather than by the consumers. Competitive market forces
have not worked well for those in greatest need. In the private sector,
demand for services is clearly related to productivity and willingness
(and ability) to pay. If left to market forces alone, inequitable distribu-
tion of healthcare would be inevitable.Valuing equity in relation to efficiency 
Decisions based on cost-effectiveness (e.g., cost per healthy life
year) may not accord well with concerns about equity. CEA calculations
are generally indifferent to equity; they are designed to steer interven-
tions to what is efficient, whatever the differential need may be. To
meet the requirements of equity, health system planners need to go
beyond ensuring equality of access to health care and must require a
balance so that health system responses are in accord with equity as
well as efficiency. 
Provided that composite indicator information is available according
to socio-economic and vulnerable groups, use of these summary indi-
cators as tools for equity by calculating healthy life per dollar to be
gained by all socio-economic and vulnerable groups could readily be
undertaken. It would be straightforward to assess the impact of specif-
ic health decisions to ensure that they enhance equity. Summary meas-
ures such as HeaLYs and DALYs can be used to guide allocation of
resources to ensure equitable distribution of those resources so as to
reach those most in need. Cost-effectiveness by itself does not provide
adequate guidance; equity should be an additional criterion to govern
the distribution of societal benefits.
Discussion 
The health of populations is the fundamental concern of global pub-
lic health. The first step in the pursuit of population health improve-
ment is the measurement of health and disease. Measurement is
required to establish the magnitude of disease problems, define causal
factors, explore potential solutions, and determine the impact of inter-
ventions. Measuring the impact of diseases on populations in terms of
mortality and morbidity and their consequences is essential for plan-
ning effective ways to reduce the burden of illness and for setting pri-
orities. 
The burden of disease in populations has been gauged in many
ways. Examples include measures of mortality such as infant mortality
rates, demographic measures such as expectation of life at birth, and
measures of morbidity such as days away from work. However, for pur-
poses of comparison among populations, and for assisting in health
planning and resource allocation, a common denominator combining
these factors is needed. Summary measures of population health based
upon the amount of healthy life time lost from disability and from death
have been developed to serve that purpose. 
Composite indicators (such as HeaLYs, DALYs and QALYs) use dura-
tion of time (years, weeks, days) to measure the loss of healthy life
from disease and the gain from interventions. These are increasingly
recognised as being important tools for assisting health related deci-
sion making. However, in order to avoid misuse, it is critical for those
using them to understand the underlying assumptions and limitations,
and also to meet the rather formidable data requirements. These sum-
mary measures could be used to examine the burden of disease
amongst sub-populations, according to socio-cultural-economic catego-
ry and especially to those groups most vulnerable, and used for ensur-
ing that health-related decisions consider equity as well as cost-effec-
tive criteria. 
Having said that, it is important to mention that while these compos-
ite measures take ICD diagnoses as a starting point for mortality and
disability, the appropriateness of the latter has been criticized.33 The
UN Convention on the Rights of Persons with Disabilities defines dis-
ability as an evolving concept resulting from the interaction of impair-
ment (when the disease process is already underway) and physical and
attitudinal environments.34 In this way, disability cannot be disentan-
gled from the social context in which these interactions take place, and
this understanding is not necessarily reflected in the current meas-
ures. New approaches for measuring disability in the general popula-











Disability and Health (ICF) have been developed and may be comple-
mentary to ICD.35
Trends in disease burden provide important clues to the success of
ongoing health programmes and the need for development of new
interventions. At the same time, they reflect non-health factors that are
important to the production or maintenance of health in populations.
Inter-country and inter-regional comparisons allow for measuring
progress among nations. They can highlight inequalities in health sta-
tus and examine these in relation to social, economic, educational, and
other factors as well. 
Health systems across the world are greatly affected by changes in
disease profiles and population dynamics. These systems must develop
the capacity to respond to such changes effectively within the
resources of each nation. Decisions should be based on evidence about
the patterns of diseases, their risk factors and effectiveness of alterna-
tive interventions. Timely collection and analysis of appropriate, high-
quality data to support such evidence are a prerequisite for improving
equitable global health development.
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